Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0153)
| Name |
Dehydroabietic acid
|
||||
|---|---|---|---|---|---|
| Synonyms |
DEHYDROABIETIC ACID; Dehydroabietate; 1740-19-8; Abieta-8,11,13-trien-18-oic acid; Abietic acid, dehydro-; (-)-Dehydroabietic acid; 13-Isopropylpodocarpa-8,11,13-trien-15-oic acid; NSC 2952; 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1R,4aS,10aR)-; CHEBI:29571; 0S5XP6S3AU; Podocarpa-8,11,13-trien-15-oic acid, 13-isopropyl-; NSC2952; Isopropyl podocarpa-8,11,13-trien-15-oic acid; NSC-2952; 6980-63-8; abieta-8(14),9(11),12-trien-18-oic acid; EINECS 217-102-8; UNII-0S5XP6S3AU; BRN 2059290; 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1R-(1alpha,4abeta,10aalpha))-; 4-09-00-02389 (Beilstein Handbook Reference); CHEMBL12850; SCHEMBL222078; DTXSID8022163; NFWKVWVWBFBAOV-MISYRCLQSA-N; Abieta-8,13-trien-18-oic acid; AMY22483; HY-N6869; (+)-Dehydroabietic acid, tech grade; BDBM50143600; MFCD09839012; AKOS015917291; CS-W012130; LMPR0104050005; (1R-(1alpha,4Abeta,10aalpha))-1,2,3,4,4a,9,10,10a-octahydro-7-isopropyl-1,4a-dimethylphenanthren-1-carboxylic acid; AC-34629; Dehydroabietic acid, >=95% (LC/MS-ELSD); FT-0633812; S3226; 13-Isopropylpodocarpa-8,13-trien-15-oic acid; EN300-6730478; A881721; Podocarpa-8,13-trien-15-oic acid, 13-isopropyl-; W-107855; Q27110153; 5-Podocarpa-8,11,13-trien-15-oic acid, 13-isopropyl-; (1R,4aS,10aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylic acid; (1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylic acid; (1R-(1ALPHA,4ABETA,10AALPHA))-1,2,3,4,4A,9,10,10A-OCTAHYDRO- 7-ISOPROPYL-1,4A-DIMETHYLPHENANTHREN-1-CARBOXYLIC ACID; 1,2,3,4,4a,9,10,10a-Octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenecarboxylic acid; 1,3,4,4a,9,10,10a-Octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenecarboxylic acid; 1-PHENANTHRENECARBOXYLIC ACID, 1,2,3,4,4A,9,10,10A- OCTAHYDRO-1,4A-DIMETHYL-7-(1-METHYLETHYL)-, (1R,4AS,10AR)-; 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-, [1R-(1,4a,10a)]-; 1-Phenanthrenecarboxylic acid,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-, [1R-(1.alpha.,4a.beta.,10a.alpha.)]-; InChI=1/C20H28O2/c1-13(2)14-6-8-16-15(12-14)7-9-17-19(16,3)10-5-11-20(17,4)18(21)22/h6,8,12-13,17H,5,7,9-11H2,1-4H3,(H,21,22)/t17-,19-,20-/m1/s; rel-(1R,4aS,10aR)-7-Isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylic acid; rel-(1R,4aS,10aR)-7-Isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylicacid
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C20H28O2
|
||||
| IUPAC Name |
(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylic acid
|
||||
| Canonical SMILES |
CC(C)C1=CC2=C(C=C1)C3(CCCC(C3CC2)(C)C(=O)O)C
|
||||
| InChI |
InChI=1S/C20H28O2/c1-13(2)14-6-8-16-15(12-14)7-9-17-19(16,3)10-5-11-20(17,4)18(21)22/h6,8,12-13,17H,5,7,9-11H2,1-4H3,(H,21,22)/t17-,19-,20-/m1/s1
|
||||
| InChIKey |
NFWKVWVWBFBAOV-MISYRCLQSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
| In total 1 item(s) under this Target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
| Target for Ferroptosis | Marker/Suppressor | ||||
| Responsed Disease | Nonalcoholic fatty liver disease | ICD-11: DB92 | |||
| Responsed Regulator | Kelch-like ECH-associated protein 1 (KEAP1) | Driver | |||
| Pathway Response | Fatty acid metabolism | hsa01212 | |||
| Ferroptosis | hsa04216 | ||||
| Pathways in cancer | hsa05200 | ||||
| Cell Process | Cell ferroptosis | ||||
| In Vitro Model | HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | |
| L-02 cells | Endocervical adenocarcinoma | Homo sapiens | CVCL_6926 | ||
| In Vivo Model |
The male C57BL/6J mice (6-8 weeks, Beijing Vital River Laboratory Animal Technology Co., Ltd., China) were exposed to 12 h of light and darkness at temperature (22 ± 2 ), humidity (55%) with free access to water and food. All the mice were acclimated for 1 week before the experiment, then the mice were fed normal chow diet (NCD) and high-fat diet (HFD, D12492) for 12 weeks. The HFD group was divided into 3 groups (HFD, low dose of DA (DA-L, 10 mg/kg/d), high dose of DA (DA-H, 20 mg/kg/d),n = 8)). DA was administered by gavage for 9 weeks, and 0.5% CMC-Na was administered by NCD and HFD.
Click to Show/Hide
|
||||
| Response regulation | Dehydroabietic acid (DA) inhibited ferroptosis and increased the expression of key genes such as ferroptosis suppressor protein 1 (FSP1) in vitro and vivo. In all, DA may bind with Keap1, activate Nrf2-ARE, induce its target gene expression, inhibit ROS accumulation and lipid peroxidation, and reduce HFD-induced nonalcoholic fatty liver disease (NAFLD). | ||||